63. Idiopathic thrombocytopenic purpura Clinical trials / Disease details
Clinical trials : 363 / Drugs : 212 - (DrugBank : 43) / Drug target genes : 47 - Drug target pathways : 138
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03692754 (ClinicalTrials.gov) | November 1, 2021 | 29/9/2018 | Atorvastatin in Management of Newly Diagnosed ITP | A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) | Immune Thrombocytopenia;Purpura, Thrombocytopenic | Drug: Atorvastatin 20mg;Drug: Atorvastatin 10mg;Drug: Dexamethasone | Shandong University | NULL | Not yet recruiting | 18 Years | 80 Years | All | 30 | Phase 2/Phase 3 | China |